Irina_Geo/iStock via Getty Images The U.S. FDA has expanded the indication of AstraZeneca's Farxiga (dapagliflozin) to treat type 2 diabetes in children as young as 10 years old.
The drug was already approved for this indication in adults. The label expansion was based on the results of the T2NOW trial that showed an adjusted mean change in A1C of -0.62% for Farxiga compared to +0.
41% for placebo. More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca’s Tagrisso gets FDA priority review in lung cancer subtype AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes.
